RxDoctor Payments Data

Zaid Aljahmi, MD

Family Medicine · Farmington Hills, MINPI 1679815112

Payments from drug & device makers

$1,998in general payments, 2019–2025

Across 77 payments — averaging $25.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$797
  • AstraZeneca$344
  • Abbott$168
  • AbbVie$158
  • Lilly USA, LLC$139
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$118
  • plus $274 from 6 others

What the payments were for

  • Food & beverage$1,98699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,998 in reported general payments places this provider in the 80th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$88,463
Medicare patients
152
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$80,799
JanuviaSitagliptin Phosphate76$47,716
LinzessLinaclotide74$41,614
FarxigaDapagliflozin Propanediol53$34,905
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$33,621
EliquisApixaban42$24,902
OzempicSemaglutide24$22,485
TrulicityDulaglutide18$18,737
WegovySemaglutide11$14,583
EntrestoSacubitril/Valsartan14$12,348
Repatha SureclickEvolocumab21$11,460
RestasisCyclosporine15$9,722
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,439
JanumetSitagliptin Phos/Metformin Hcl13$8,529
Janumet XrSitagliptin Phos/Metformin Hcl14$7,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Restasis$158$51,33789 claims
AstraZenecaFarxiga, Symbicort$344$40,36373 claims
GSKTrelegy Ellipta$797$33,62152 claims
Lilly USA, LLCTrulicity$139$18,73718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →